EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report

Anna M G Pasmooij iD, Peter G M Mol iD, Jacob Cornelis Bot iD, Hubert G M Leufkens iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Anna M G Pasmooij und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Medicines Evaluation Board, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Pharmacology, Clinical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the Netherlands, drug regulatory science is a vibrant national and internationally oriented community. In this review, we present the factors that have contributed to this successful collaboration between relevant stakeholders and that led to a surge of activities around how regulatory science became embedded in the ecosystem of medicines research, clinical pharmacology, policymaking and regulation. We distinguished three pivotal episodes: (i) TI Pharma Escher‐project, (ii) Dutch Medicines Evaluation Board as catalyst of the big jump, and (iii) Regulatory Science Network Netherlands and multistakeholder engagement. The research agenda has been influenced by the dynamic evolution of legal frameworks in Europe, such as the EU orphan medicines legislation of 2001 and the EU pharmacovigilance legislation of 2012. All these developments have inspired and have raised pertinent regulatory sciences questions. Furthermore, clinical pharmacology as a discipline has been very influential in shaping regulatory science, contributing to discussions on the level of clinical evidence that is necessary to justify marketing approval of a new medicine. With a growing interest of multiple parties such as academics, European Medicines Agency, national agencies, patient organizations and EFPIA, connecting regulatory science activities is key.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacology, ClinicalNetherlandsHumansDrug and Narcotic ControlDrug ApprovalLegislation, DrugPharmacovigilanceEuropean UnionPolicy Making

Autor:innen und Institutionen

  • Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
  • Regulatory Science Network Netherlands, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Janssen Biologics BV, Leiden, The Netherlands.
  • Lygature, Utrecht, The Netherlands.

ORCID-Profile: Anna M G Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubert G M Leufkens

Zitieren

APA

Pasmooij, A. M. G., Mol, P. G. M., Bot, J. C., & Leufkens, H. G. M. (2024). The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3275

Vancouver

Pasmooij AMG, Mol PGM, Bot JC, Leufkens HGM. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3275

BibTeX
@article{Pasmooij2024,
  author = {Pasmooij, Anna M G and Mol, Peter G M and Bot, Jacob Cornelis and Leufkens, Hubert G M},
  title = {The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3275}
}
Kostenlos starten →